Click here for slides on this topic


ORIGIN

A randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes. The factorial design of ORIGIN allowed for examination of two interventions in a single study. Via two arms, the study investigated whether insulin replacement therapy with insulin glargine targeting fasting normoglycemia (FPG ≤95 mg/dL) reduces CV outcomes more than standard approaches, and whether the addition of omega-3 fatty acids reduces CV death.
The following content matched the glossary term: ORIGIN

NDEI.org Expert Commentary Silvio E. Inzucchi MD on the Association Between Severe Hypoglycemia

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "This paper adds to a growing body of literature demonstrating the higher cardiovascular risk of patients with type 2 diabetes and a history of severe hypoglycemia"

Clinical Insights in Diabetes Newsletter July 2013

Top

Clinical Insights® in Diabetes newsletter July 2013

Carotid intima-media thickness (CIMT) change in ORIGIN-GRACE, effects of omega-3 fatty acids on CV events in the Risk and Prevention Study, canagliflozin therapy in CANTATA-D2 and CANTATA-M, weight gain and intensive therapy in ACCORD, glycemic control with single daily basal insulin plus corrective glulisine and basal bolus regimen, diurnal pattern to insulin action in type 1 diabetes.

Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: ORIGIN-GRACE

Top

Lonn EM, Bosch J, Diaz R, et al; for the GRACE and ORIGIN Investigators. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE). Diabetes Care. 2013;36(9):2466-2474. Findings from ORIGIN-GRACE showed no difference in annualized change in maximum carotid intima-media thickness for 12 carotid artery segments with insulin glargine or omega-3 fatty acid.

NDEI.org Press Release Vivian Fonseca, MD, on “Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit” in the ORIGIN Trial

Top

Vivian Fonseca, MD, on the "Futility of Adding Omega-3 Fatty Acids in the Hope of Added Benefit" in the ORIGIN Trial July 31, 2012: NDEI.org, the official website of The National Diabetes Education Initiative® (NDEI®), published today a webcast on the results of the ORIGIN trial featuring expert commentary from Vivian A. Fonseca, MD. “These results may help us to education our patients on the futility of adding omega-3 fatty acids in the hope of added benefit, in the absence of data supporting their use,” said Dr Fonseca, a Professor of Medicine and Pharmacology, and Chief of the Section of Endocrinology at Tulane University Health Sciences Center in New Orleans, Louisiana.

Press Room

Top

NDEI.org press releases and news.

Fonseca Commentary

Top

ORIGIN: The Effects of Insulin Glargine and Omega-3 Fatty Acids on Cardiovascular Death in Diabetes or Prediabetes. NDEI.org Education Council Member Vivian A. Fonseca, MD, provides expert commentary on the clinical implications of the ORIGIN omega-3 trial results.

NDEI.org Expert Commentary on ORIGIN Glargine Trial Silvio Inzucchi, MD

Top

Expert commentary on ORIGIN glargine diabetes trial Silvio Inzucchi, MD.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

1 2 3 Next 

Slide Library Results

Search Results for: ORIGIN Slides Found: 82
Whitehall II: Design
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
ORIGIN: Design
ORIGIN-GRACE: Design
ORIGIN-GRACE: Primary and Secondary Outcomes
ORIGIN-GRACE: Select Baseline Characteristics
ORIGIN-GRACE: No Difference in Annualized Change in Max CIMT for 12 Carotid Artery Segments with Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Glargine, Not Omega-3 Fatty Acid, Improves Annualized Change in Max CIMT
ORIGIN-GRACE: No Difference in Annualized Change in Max Far Wall CIMT for Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Major Cardiovascular Events
ORIGIN-GRACE: Summary of Findings
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
ACC/AHA Cholesterol Guidelines 2013: Statin Benefit Groups for ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Primary Prevention LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 3: Primary Prevention Diabetes
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 4: Primary Prevention With 10-Yr ASCVD Risk 7.5% or Higher (No Diabetes)
ACC/AHA Cholesterol Guidelines 2013: The Argument Against LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: Diabetes & LDL-C 70-189
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
ACC/AHA Cholesterol Guidelines 2013: High-Intensity Statin for Secondary ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: Secondary ASCVD Prevention for Age >75 Years
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
ACC/AHA Cholesterol Guidelines 2013: 10-Yr ASCVD Risk Assessment Calculator: Primary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Maximizing Statin Safety
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: CK & ALT
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Statin Dosing
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
ACC/AHA Cholesterol Guideline 2013: Statin Safety Recommendations: Cognitive Impairment
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Niacin
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Bile-Acid Sequestrants & Ezetimibe
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Fibrates
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Omega-3 Fatty Acids
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
ACC/AHA Cholesterol Guidelines 2013: Monitoring & Optimizing Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Insufficient Response to Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Estimated 10-Yr ASCVD Risk Guides Statin Therapy
Insulin Glargine Neutral on CV Outcomes & Cancer Diabetes ORIGIN | NDEI
Neutral Omega-3 Effect on CV Outcomes in ORIGIN Diabetes | NDEI
Insulin Glargine A1C Reduction Type 2 Diabetes PPT | NDEI
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
ORIGINALE No Increase in CV Events or Cancer with Insulin Glargine Diabetes | NDEI
ORIGINALE No Effect of Omega-3 Fatty Acids on CV Outcomes | NDEI
ORIGINALE A1C Reduction With Insulin Glargine Type 2 Diabetes | NDEI